Viemed Healthcare Reports Q3 2026 Growth Driven by Sleep Therapy and Maternal Health
Viemed Healthcare (VMD) reported strong third-quarter 2026 financial results, highlighted by a 12.2% year-over-year increase in net revenue to $80.7 million. The company saw significant growth in its sleep therapy segment, with PAP therapy patients increasing by 37.5% year-over-year. Net income attributable to Viemed rose 32% compared to the prior-year quarter, benefiting from improved operating leverage and a sequential expansion of adjusted EBITDA margins to 21.1%. Despite the strong operational performance, the company noted challenges regarding accounts receivable, which rose to $34.9 million due to system migration delays and audit-related payment timing issues. Management also highlighted increased administrative costs stemming from heightened enforcement and claims audit activity. Looking ahead, Viemed provided updated full-year revenue guidance of $316 million to $320 million and narrowed its adjusted EBITDA guidance to $64 million–$66 million.
Tickers: $VMD
Topics: EBITDA Maternal Health Services Net Income Revenue Growth Sleep Therapy Services
Read the full article at Motley Fool
Part of the story Sotera Health Reports Q3 2026 Growth Driven by Sterigenics and Nelson Labs (5 articles)